Mandate

Vinge advises on Artimplant’s rights issue

January 17, 2012

Vinge has advised Artimplant AB (publ) in connection with its rights issue of units (shares and warrants) and reduction of the company’s share capital. Artimplant is listed on NASDAQ OMX Stockholm.

Vinge’s team consisted of Andrs Strid, Anna Björk Larsson, Emma Kero Ljungberg and Michele Fara.

Related

Vinge advises SAGA Diagnostics AB on convertible note issue

SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023

Vinge has advised private equity firm Stirling Square Capital Partners

Vinge has advised private equity firm Stirling Square Capital Partners in connection with its acquisition of a majority stake in Infobric, a leading provider of software solutions for the construction industry, from Summa Equity.
September 22, 2023